Back to Search Start Over

Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation.

Authors :
Yoshizato T
Nannya Y
Atsuta Y
Shiozawa Y
Iijima-Yamashita Y
Yoshida K
Shiraishi Y
Suzuki H
Nagata Y
Sato Y
Kakiuchi N
Matsuo K
Onizuka M
Kataoka K
Chiba K
Tanaka H
Ueno H
Nakagawa MM
Przychodzen B
Haferlach C
Kern W
Aoki K
Itonaga H
Kanda Y
Sekeres MA
Maciejewski JP
Haferlach T
Miyazaki Y
Horibe K
Sanada M
Miyano S
Makishima H
Ogawa S
Source :
Blood [Blood] 2017 Apr 27; Vol. 129 (17), pp. 2347-2358. Date of Electronic Publication: 2017 Feb 21.
Publication Year :
2017

Abstract

Genetic alterations, including mutations and copy-number alterations, are central to the pathogenesis of myelodysplastic syndromes and related diseases (myelodysplasia), but their roles in allogeneic stem cell transplantation have not fully been studied in a large cohort of patients. We enrolled 797 patients who had been diagnosed with myelodysplasia at initial presentation and received transplantation via the Japan Marrow Donor Program. Targeted-capture sequencing was performed to identify mutations in 69 genes, together with copy-number alterations, whose effects on transplantation outcomes were investigated. We identified 1776 mutations and 927 abnormal copy segments among 617 patients (77.4%). In multivariate modeling using Cox proportional-hazards regression, genetic factors explained 30% of the total hazards for overall survival; clinical characteristics accounted for 70% of risk. TP53 and RAS-pathway mutations, together with complex karyotype (CK) as detected by conventional cytogenetics and/or sequencing-based analysis, negatively affected posttransplant survival independently of clinical factors. Regardless of disease subtype, TP53 -mutated patients with CK were characterized by unique genetic features and associated with an extremely poor survival with frequent early relapse, whereas outcomes were substantially better in TP53 -mutated patients without CK. By contrast, the effects of RAS-pathway mutations depended on disease subtype and were confined to myelodysplastic/myeloproliferative neoplasms (MDS/MPNs). Our results suggest that TP53 and RAS-pathway mutations predicted a dismal prognosis, when associated with CK and MDS/MPNs, respectively. However, for patients with mutated TP53 or CK alone, long-term survival could be obtained with transplantation. Clinical sequencing provides vital information for accurate prognostication in transplantation.<br /> (© 2017 by The American Society of Hematology.)

Details

Language :
English
ISSN :
1528-0020
Volume :
129
Issue :
17
Database :
MEDLINE
Journal :
Blood
Publication Type :
Academic Journal
Accession number :
28223278
Full Text :
https://doi.org/10.1182/blood-2016-12-754796